Results 151 to 160 of about 1,471,493 (261)
Live Plague Vaccine Development: Past, Present, and Future
During the last 100 years, vaccine development has evolved from an empirical approach to one of the more rational vaccine designs where the careful selection of antigens and adjuvants is key to the desired efficacy for challenging pathogens and/or ...
Anastasia S. Vagaiskaya +3 more
core +1 more source
Phenylboronic acid‐functionalized gold nanoparticles reversibly attach to cell‐surface glycans, enhancing photoporation‐mediated intracellular delivery. After irradiation, ATP competitively disrupts the boronic ester interactions and removes cell‐associated nanoparticles, markedly reducing residual gold.
Tao Lu +15 more
wiley +1 more source
This work presents a clinically deployable simultaneous PET/MRI workflow which integrates hyperpolarized 13C imaging of metabolism and extracellular pH with [18F]FMISO PET to characterize hypoxia, acidosis, and metabolic reprogramming in feline sarcoma.
Martin Grashei +17 more
wiley +1 more source
After IAV infection, NS1 induces PARP1 phase transition, reducing molecular mobility in condensates, prolonging host transcriptional pause, aiding RdRp cap snatching, and promoting viral transcription. ABSTRACT Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive.
Shufeng Ma +12 more
wiley +1 more source
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source
Influenza vaccine : what you need to know : (flu vaccine, live, intranasal) 2013-2014 [PDF]
1. Why get vaccinated? -- 2. Live, attenuated flu vaccine-LAIV, Nasal Spray \ue2\u20ac\u201c 3. Some people should not get this vaccine \ue2\u20ac\u201c 4. Risks of a vaccine reaction \ue2\u20ac\u201c 5. What if there is a serious reaction?
core
Here, a PDL1 inhibitor is employed as a fifth component to modify lipid nanoparticles (LNPs). PDL1 inhibitor‐loaded LNPs show enhanced lymph node targeting, resulting in greater lymph node expansion, immune cell infiltration, and improved mRNA vaccine efficacy. This fifth component LNP could be a novel platform for mRNA vaccines.
Minki Ha +5 more
wiley +1 more source
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu +10 more
wiley +1 more source
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang +8 more
wiley +1 more source
Sarbecovirus ORF9b recruits host phosphatase PPM1A to suppress innate immunity through dual mechanisms. PPM1A directly dephosphorylates ORF9b to sustain its activity and indirectly downregulates STAT2 phosphorylation to impair interferon signaling. Pharmacological inhibition of PPM1A restores antiviral responses and limits sarbecovirus replication ...
Lixiang Xie +24 more
wiley +1 more source

